InnovationAus.com’s Post

Sharing our latest publication on comparative approaches to measuring hospitalisation trends 📈 in acute coronary syndrome (ACS). By linking complex cardiac biomarker data 🧪to electronic hospital and emergency records, our study assessed trends in ACS according to biomarker status, enhancing the interpretation of administratively derived population-level ACS data and its subtypes💙. https://lnkd.in/dTP4A7Ta #CERC #Biomarker #LinkedData School of Population & Global Health, UWA

NICE - National Institute for Health and Care Excellence Institute for Health and Care Excellence Forward View 2024-2025 NICE has released their forward view for 2024-2025, outlining the key priority areas that will guide their efforts in the coming year. Their goal is to ensure that patients receive the most effective treatments promptly, while also delivering value to the taxpayer. These priorities are set to be reviewed and refreshed annually to stay responsive to significant developments and innovations in life sciences, health, and care. NICE’s Priority Areas: 🔹 Mental Health 🔹 Early Cancer Detection/Diagnosis 🔹 Diabetes 🔹 Musculoskeletal Conditions 🔹 Women’s Health 🔹 Respiratory 🔹 Neurology NICE’s horizon scanning function is actively evaluating emerging trends in health and care. Over the next 2-5 years, they anticipate reviewing new innovations in underserved clinical areas and exploring evolving delivery models to enhance existing treatments. They are particularly focused on new pharmacological treatments, advanced therapy medicinal products, and personalized medicine driven by high-throughput sequencing and AI. Do you need support to be compliant with the #UK, #European or #Swiss regulatory requirements for medical devices or #IVDs ? Reach out to us ☞ meetus@taoexcellence.ch #HealthcareExcellence #NICEGuidelines #HealthInnovation #StrategicPriorities #LifeSciences #FutureOfHealthCare #medtech #regulatoryaffairs #regulatorycompliance #invitrodiagnostics #clinicalaffairs #artificialintelligence #AI #publichealth #patientcare #healthtech

Research has shown that rural residents often face challenges in accessing timely and comprehensive healthcare. Limited availability of specialized services, long travel distances, and fewer healthcare providers contribute to disparities, impacting early detection and treatment outcomes for gynecologic cancers. We recommend these three tips for rural patients navigating gynecologic cancer or other conditions that require medical intervention. #NationalRuralHealthDay #PowerofRural Learn more: https://shorturl.at/XYX8G

I am often asked “What are the U.K. Life Sciences Missions” and “what is their focus”. The Missions are intended to apply a Vaccine Taskforce-type approach by bringing together industry, academia, the third sector and the NHS to collaborate to make progress in specific disease areas, by advancing early disease prevention, diagnosis, treatment, monitoring, and developing breakthrough products and technologies to save lives. The five current Missions are in the disease areas of dementia, cancer, mental health, obesity and addiction. It is a true privilege to have the opportunity to learn from, be inspired by and partner with the other Mission chairs - each of whom brings their unique perspective, background and expertise to how we can innovate and help address some of the biggest healthcare challenges being faced by the U.K.

Excited about this collaboration between CEVR and Tempus AI, where we used real-world claims data linked to insurance coverage policy characteristics developed by the CEVR team to explore how policy complexity may impact patient outcomes! Reach out here, or stop by the poster!

The prevalence of MASH continues to increase steadily on a global scale, underscoring the urgent need for therapeutic options for a diverse and growing patient population in MASH. While there is now an approved therapy, more therapeutic options are critically needed, including multiple modalities and potential combinations, for patients to have optimal treatment.   To learn more about our pipeline, visit: https://lnkd.in/guaY8Zz   #MASH #NASH #CardiometabolicDiseases  

At Fibronostics, we are proud to lead the way in advancing liver health with our revolutionary tools, LIVERFASt and LIVERSTAT. Designed as noninvasive software solutions, these tools empower healthcare professionals to perform accurate liver screening, transforming the way we approach liver disease management. Here’s why they’re game-changers: ✅ Noninvasive: No need for painful biopsies—our tools rely on routine blood test data.
 ✅ Accurate and Actionable Insights: Quickly assess liver fibrosis, steatosis, and inflammation.
✅ Convenient and Scalable: Ideal for clinics, hospitals, and health programs looking to screen large populations efficiently.
 ✅ Empowering Early Detection: Early intervention saves lives, and our tools make it easier than ever to identify at-risk individuals.
 ✅ Cost-Effective: Reduce the burden of invasive diagnostics and associated healthcare costs. In a world where liver disease is often diagnosed too late, LIVERFASt and LIVERSTAT offers a proactive approach, empowering providers to screen, monitor, and manage liver health with confidence. Let’s work together to redefine liver health management. #LiverHealth #Innovation #NoninvasiveTechnology #LIVERFASt #LIVERSTAT #Fibronostics

Breast Cancer Network Australia (BCNA) is proud to have its Chief Executive Officer, Kirsten Pilatti, appointed as a member of the newly formed Health Technology Assessment (HTA) Review Implementation Advisory Group (IAG). The HTA was announced today by the Albanese Government and marks a significant step toward generational reform in Australia’s healthcare system. “The Health Technology Assessment (HTA) is a vital system that must ensure all Australians have access to the best possible treatments in a timely manner. For decades, BCNA has called for reform to the HTA process, and we feel deeply privileged to have a seat at the table. I am committed to ensuring that the consumer voice is heard and that lived experience shapes our healthcare system at every level.” - BCNA CEO Kirsten Pilatti You can read more information about the announcement at https://lnkd.in/gBCWwjYk #BreastCancerAwareness #HealthTechnology #HealthcareReform #AustralianHealthcare #HealthEquity #PatientAdvocacy

The future of healthcare is here, and it’s time to explore the transformative potential of GLP-1 medications. Originally developed for diabetes management, these versatile therapies are now demonstrating groundbreaking benefits across a spectrum of conditions—from reducing cancer risk to improving cardiovascular and reproductive health. Join us at the Wednesday Specialty GLP-1 Summit at HLTH USA where our CEO, Rob MacNaughton will be leading a conversation with other thought leaders on: - Cutting-edge insights on the expanding role of GLP-1s - Integrative approaches combining GLP-1s with lifestyle interventions - Challenges and opportunities ahead as the demand for GLP-1s rise We’re delivering results that are life-changing, and we have the data to #ProveIt.

⭐ Company Spotlight: Meet QuanBio.com ⭐ Did you know: Cardiovascular issues, often referred to as silent killers, are typically diagnosed too late, when arteries are often up to 95% blocked. QuanBio's mission is to change that narrative by providing an affordable, accessible, and innovative solution. QuanBio, located at NJII's Incubator in Newark, is a groundbreaking company at the forefront of cardiovascular health innovation. Co-founded by Astrid Androsch and Dr. Vlad Friedman, a New York Presbyterian cardiologist, the company aims to address a significant gap in the healthcare system: early detection of cardiovascular disease. Read our latest spotlight on QuanBio and learn more about how they're transforming detection with AI and science to revolutionize cardiovascular health: https://lnkd.in/eWb9Epy6 #cardiovascularhealth #QuanBio #healthinnovation #vascularhealth #companyspotlight #NJII #healthtech